



HAL
open science

Chronic kidney disease and cancer: a troubling connection.

Bénédicte Stengel

► **To cite this version:**

Bénédicte Stengel. Chronic kidney disease and cancer: a troubling connection.: CKD and cancer. Journal of Nephrology, 2010, 23 (3), pp.253-62. inserm-00555055

HAL Id: inserm-00555055

<https://inserm.hal.science/inserm-00555055>

Submitted on 12 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 2 - Relative risk of cancer in patients with non end-stage CKD and in those on dialysis or with a kidney transplant for end-stage CKD

Cancer site	Non end-stage CKD			Dialysis			Kidney Transplant		
	[Ref]	n	RR or HR (95%CI) ^{a,b} or SIR (95%CI) ^c	[Ref]	n	SIR (95%CI)	[Ref]	n	SIR (95%CI) or RR (95%CI) ^d
All cancer	[17]	M : 245	1.3 (1.1,1.5) ^a	[9] ANZ	500	1.8 (1.7,2.0)	[11]	639	3.9 (3.6,4.2)
		W : 237	1.0 (0.9,1.2) ^a	[9] Euro	6,849	1.1 (1.0,1.1)	[12] ^d	-	-
	[16]	590	1.2 (p<0.001) ^b	[9] USA	17,695	1.2 (1.2,1.2)	[14]	778	2.5 (2.3,2.7) ^e
	[13]	689	1.2 (1.1,1.3) ^c	[13]	870	1.4 (1.3,1.5)	[13]	1,236	3.3 (3.1,3.5) ^e
Genitourinary									
Kidney	[16]	17	1.4 (1.0,2.1) ^b	[9] ANZ	70	9.8 (7.7,12.3)	[11]	28	5.2 (3.4,7.5)
	[13]	193	13.2 (11.4,15.1) ^c	[9] Euro	680	3.3 (3.1,3.6)	[12] ^d	-	14.6
				[9] USA	1,303	3.7 (3.5,3.9)	[14]	71	7.3 (5.7,9.2)
				[13]	86	5.6 (4.5,7.0)	[13]	70	7.3 (5.7,9.2)
Bladder (B) or urinary tract (UT)	[17]	M : 16 (UT)	5.0 (p<0.04) ^{a†}	[9] ANZ	53	4.8 (3.6,6.2)	[11]	-	-
	[16]	35 (B)	1.8 (1.5,2.3) ^b	[9] Euro	660	1.5 (1.4,1.7)	[12] ^d	-	3.6
	[13]	85 (B)	2.7 (2.2,3.4) ^c	[9] USA	933	1.4 (1.3,1.5)	[14]	24	2.0 (1.3,3.0)
				[13]	63	2.2 (1.7,2.9)	[13]	42	3.3 (2.4,4.5)
Uterus cervix	[13]	11	1.6 (0.8,2.9) ^c	[9] ANZ	15	4.0 (2.4,6.6)	[11]	-	-
				[9] Euro	146	1.6 (1.3,1.8)	[12] ^d	-	5.7
				[9] USA	290	2.5 (2.2,2.8)	[14]	6	1.6 (0.6,3.4)
				[13]	13	2.6 (1.4,4.4)	[13]	13	2.5 (1.3,4.3)
Prostate	[17]	62	NS	[9] ANZ	36	1.2 (0.9,1.7)	[11]	20	1.1 (0.7,1.7)
	[16]	110	1.0 (0.9,1.3)	[9] Euro	422	0.9 (0.8,1.0)	[12] ^d	-	1.6
	[13]	153	1.2 (1.0, 1.4)	[9] USA	2,018	0.7 (0.6,0.7)	[14]	37	0.9 (0.6,1.3)
				[13]	74	0.7 (0.5,0.8)	[13]	41	1.0 (0.7,1.3)
Hematopoietic									
Non-Hodgkin lymphoma	[13]	35	1.5 (1.1,2.1)	[9] ANZ	11	1.4 (0.8,2.6)	[11]	27	3.8 (2.5,5.6)
				[9] Euro	102	0.6 (0.5,0.8)	[12] ^d	-	29.1
				[9] USA	736	1.7 (1.5,1.8)	[14]	155	9.9 (8.4-11.5)
				[13]	35	1.5 (1.1,2.1)	[13]	125	8.8 (7.4,10.5)
Leukemia	[13]	16	0.9 (0.5,1.4)	[9] ANZ	11	1.4 (0.8,2.6)	[11]	-	-
				[9] Euro	102	0.6 (0.5,0.8)	[12] ^d	-	7.9
				[9] USA	736	1.7 (1.5,1.8)	[14]	17	2.3 (1.3,3.6)
				[13]	35	1.5 (1.1,2.1)	[13]	24	2.5 (1.7,3.7)

Oral cavity									
Lip (L)	[13]	22 (L)	1.9 (1.2,2.8) ^c	[9] ANZ	3 (T)	1.9 (0.6-5.9)	[11]	39 (L)	54.8 (39.0,74.9)
Tongue (T)				[9] Euro	90(T)	2.0 (1.6-2.5)	[12] ^d	- (M)	11.1
or Mouth (M)				[9] USA	144(T)	1.8 (1.5-2.1)	[14]	54 (L)	31.3 (23.5,40.8)
				[13]	29 (L)	3.7 (2.5-5.3)	[13]	283 (L)	47.1 (42.8,52.3)
Digestive									
Colon	[17]	M :35 F :41	NS NS	[9] ANZ	49	1.1 (0.9,1.5)	[11]	25	2.4 (1.5,3.5)
	[16]	90	1.1 (1.0,1.4) ^b	[9] Euro	831	0.9 (0.9,1.0)	[12] ^d	-	2.8
	[13]	83	1.3 (1.1,1.7) ^c	[9] USA	2,343	1.2 (1.1,1.2)	[14]	51	1.4 (1.0,1.8)
				[13]	78	1.2 (0.9,1.5)	[13]	82	2.4 (1.9,2.9)
Liver	[13]	4	2.9 (0.8,7.3) ^c	[9] ANZ	3	1.5 (0.5,4.6)	[11]	-	-
				[9] Euro	162	1.2 (1.0,1.4)	[12] ^d	-	4.5
				[9] USA	192	1.5 (1.3,1.7)	[14]	5	1.8 (0.6,4.3)
				[13]	14	2.3 (1.3,3.8)	[13]	10	3.2 (1.5,5.9)
Skin									
Melanoma (MA)		79 (MA)	1.0 (0.8,1.3)	[13]	57 (MA)	1.0 (0.8,1.4)	[11]	267 (NMA)	57.7 (51.0,65.1)
Nonmelanoma skin (NMA)	[13]	3 (K)	19.6 (4.1, 57.4)		6 (K)	58.9 (21.2,126.0)	[12] ^d	- (NMA)	92.3
Kaposi sarcoma (K)							[14]	20 (MA)	1.9 (1.2,3.0)
							[13]	111 (MA)	2.5 (2.1,3.1)
Other									
Lung	[17]	M :27 F :18	9.0 (2.0, 30.0) ^{a†} NS	[9] ANZ	57	1.4 (1.1,1.8)	[11]	24	1.7 (1.1,2.5)
	[16]	77	1.2 (1.0,1.5) ^b	[9] Euro	978	0.9 (0.8,0.9)	[12] ^d	-	3.6
	[13]	34	1.1 (0.7,1.5)	[9] USA	2,901	1.1 (1.1,1.2)	[14]	108	2.1 (1.7,2.5)
				[13]	135	1.6 (1.3,1.9)	[13]	102	1.7 (1.1,2.5)
Thyroid	[13]	15	2.6 (1.4,4.2)	[9] ANZ	11	5.9 (3.3,10.7)	[11]	6	3.8 (1.4,8.2)
				[9] Euro	87	1.9 (1.5,2.3)	[12] ^d	-	14.7
				[9] USA	216	2.4 (2.1,2.8)	[14]	31	6.9 (4.7,9.8)
				[13]	38	9.2 (6.5,12.7)	[13]	23	5.0 (3.1,7.4)

N : number of observed cancers ; SIR : standardized incidence ratio ; RR : relative risk or rate ratio ; HR : hazard ratio ; 95% CI : 95% confidence interval ; NS : non significant ; NA : not available because of insufficient number of cancer cases ; M : men ; W : women

eGFR : estimated GFR with the abbreviated MDRD equation in ml/min/1.73 m² ;

^aPer 10 ml/min/1.73 m² decrease in eGFR ; ^{a†}HR for an eGFR < 40 as compared to > 40 ml/min/1.73 m² , adjusted for age, smoking, sun-related skin damage and blood pressure

^bHR of cancer per 1-SD increase of log ACR, ^cSIR of cancer up to 5 yrs before RRT as compared to the general population

^dAge-adjusted rate ratio (n cases and CI not available) for cancer in women (except for prostate) 3 years after kidney transplantation

^eExcluding nonmelanoma skin cancer